Nasus Pharma director reports option holdings

Nasus Pharma Ltd director Shacham Sharon has reported existing option holdings in the company.

Rhea-AI Filing Summary

Nasus Pharma Ltd director Shacham Sharon has reported existing option holdings in the company. The filing shows options to purchase 10,000 Ordinary Shares, granted on December 11, 2025, vesting 2.0833% monthly. As of March 18, 2026, all 10,000 options remain outstanding, with 625 vested and exercisable at an exercise price of $5.38 per share, expiring on December 11, 2035.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shacham Sharon

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nasus Pharma (NSRX) director Shacham Sharon report in this Form 3?

Director Shacham Sharon reported existing derivative holdings in Nasus Pharma. The filing lists options to purchase 10,000 Ordinary Shares, providing transparency on equity-based compensation and potential future share ownership from these options.

How many Nasus Pharma (NSRX) shares are covered by Sharon’s options?

The options cover 10,000 Ordinary Shares of Nasus Pharma. This represents the maximum number of shares that could be acquired through this specific option grant if fully vested and exercised under the disclosed terms.

What is the exercise price and expiry of Sharon’s Nasus Pharma (NSRX) options?

The options have an exercise price of $5.38 per Ordinary Share and expire on December 11, 2035. These terms define the cost to acquire shares and the final date by which the options must be exercised.

How do Sharon’s Nasus Pharma (NSRX) options vest under this grant?

The options vest at a rate of 2.0833% of the total grant each month after December 11, 2025. This gradual vesting schedule ties equity ownership to continued service over time, rather than granting full access immediately.

How many of Sharon’s Nasus Pharma (NSRX) options are currently exercisable?

As of March 18, 2026, 625 of the 10,000 options are vested and exercisable. The remaining options are still unvested but outstanding, following the monthly vesting pattern established at the grant date.

Does this Nasus Pharma (NSRX) Form 3 show any recent insider buying or selling?

The Form 3 reflects existing option holdings rather than new market trades. It discloses Sharon’s position in stock options, without reporting open-market purchases or sales of Nasus Pharma’s Ordinary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 08:56 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shacham Sharon

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)(1)	03/11/2026	12/11/2035	Ordinary Shares	10,000	$5.38(1)	D

Explanation of Responses:

1. Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.

	/s/ Sharon Shacham	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)